Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment

Status Recruiting

Clinical Trial Summary

Cerebral small vessel disease is a common cause of cognitive impairment. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion and increase cerebral blood flow. Patients with cognitive impairment, preserved basic activities of daily living, and brain computed tomography (CT) or magnetic resonance imaging (MRI) evidence of confluent white matter hyperintensities or multiple brain infarcts will be randomized to either RIC performed once a day on one arm, or twice per day on one arm, for 30 days, to test tolerability and effects on MRI markers of blood flow.

Clinical Trial Description

Cerebral small vessel disease (cSVD) accounts for 20-25% of all strokes and is the most common cause of vascular cognitive impairment (VCI) as well as a major contributor to mixed dementia, potentially interacting with Alzheimer's disease. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion. This is a prospective, open-label randomized controlled clinical trial with blinded endpoint assessment (PROBE). Participants that complete a 14-day run-in period will be randomized to 30 days of either: a) RIC performed once per day on one arm, or b) RIC performed twice per day on one arm. Each RIC session will consist of 4 cycles of unilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes, administered by modified blood pressure monitor (under an Investigational Trail Authorization from Health Canada). The primary outcome is tolerability, defined as the proportion in each trial arm that complete 80% or more of the assigned RIC sessions. Secondary outcomes will include pain scores, cognition, and MRI markers of cerebral blood flow and white matter integrity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04109963
Study type	Interventional
Source	University of Calgary
Contact	Eric E Smith, MD
Phone	1-403-944-1594
Email	eesmith@ucalgary.ca
Status	Recruiting
Phase	Phase 2
Start date	September 26, 2019
Completion date	March 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04567745` - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers	Phase 1
Recruiting	`NCT04335994` - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	N/A
Not yet recruiting	`NCT06416371` - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Completed	`NCT01761227` - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia	Phase 2
Active, not recruiting	`NCT01208675` - The Swedish BioFINDER Study
Completed	`NCT00165763` - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia	Phase 4
Completed	`NCT00621647` - Seroquel- Agitation Associated With Dementia	Phase 3
Recruiting	`NCT04095962` - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia	N/A
Recruiting	`NCT03275363` - The University of Hong Kong Neurocognitive Disorder Cohort	N/A
Active, not recruiting	`NCT03804229` - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia	Phase 3
Enrolling by invitation	`NCT03724136` - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study	N/A
Completed	`NCT02453932` - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia	Phase 3
Completed	`NCT00947531` - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia	Phase 4
Not yet recruiting	`NCT03702543` - Managing Vascular Dementia Risk Factors With SymTrend	Phase 1
Enrolling by invitation	`NCT02147652` - Personalized Music Therapy and Agitation in Dementia	N/A
Recruiting	`NCT04114994` - Longitudinal Cognitive Assessment by BoCA
Recruiting	`NCT06034509` - Cognitive and Vascular Functioning Following TBI
Recruiting	`NCT05921266` - Urolithin A Supplementation in Middle-aged Adults With Obesity	N/A
Completed	`NCT01465360` - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center	N/A
Not yet recruiting	`NCT01466543` - Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment — TRIC-VCI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms